JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Minerva Neurosciences Inc

Uždarymo kaina

4.64 -5.31

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.55

Max

4.75

Pagrindiniai rodikliai

By Trading Economics

P/E

Sektoriaus vid.

1.717

37.461

Pelnas, tenkantis vienai akcijai

-0.43

Darbuotojai

8

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.4M

15M

Ankstesnė atidarymo kaina

9.95

Ankstesnė uždarymo kaina

4.64

Minerva Neurosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-21 15:58; UTC

Pagrindinės rinkos jėgos

Minerva Shares Soar on $200 Million Financing for Schizophrenia Drug Trial

Akcijų palyginimas

Kainos pokytis

Minerva Neurosciences Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

$

Apie bendrovę Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
help-icon Live chat